Skip to content
Geltides
Apply for wholesale

SubFlux RGJ26 delivery route

Topical

Enhanced transdermal permeation

Wholesale gel-based peptides for topical use, sold to brands, clinics, and distributors across the United States.

Last updated 7 October 2026.

Apply for wholesaleOrder samples

From the overview

What does the overview say about topical delivery?

Enhanced transdermal permeation. In the MatTek hyaluronic acid study, HA with SubFlux RGJ26 measured 527 ng/mL, against 254 for HA alone and 216 untreated. HCG (approximately 35 KDa) applied with SubFlux RGJ26 showed definitive presence in blood after 4 hours.
Lab study

Hyaluronic acid permeation study (MatTek)

Using 1300 KDa HA, the evaluation measured transdermal permeation across untreated, HA-only, unprocessed-component, and SubFlux RGJ26 conditions.

Hyaluronic acid permeation study (MatTek). Permeation in ng/mL by condition.
  • Untreated216ng/mL
  • HA alone254ng/mL
  • HA + unprocessed components160ng/mL
  • HA + SubFlux RGJ26 processed technology527ng/mL
Case study

Transdermal HCG case study

HCG (approximately 35 KDa) applied with SubFlux RGJ26 showed definitive presence in blood after 4 hours.

Lab study

Safety studies (MatTek)

No structural damage or tissue morphology changes were observed across multiple compounds.

See the limits of this evidence on the SubFlux RGJ26 page.

FAQ

What evidence supports topical delivery?

2.4× higher than untreated, 2.1× higher than HA alone for the MatTek hyaluronic acid study. HCG (approximately 35 KDa) applied with SubFlux RGJ26 showed definitive presence in blood after 4 hours. No structural damage or tissue morphology changes were observed across multiple compounds.

Other routes

Partnership, licensing, technical collaboration

Which topical formula are you building?

Tell us the peptides you want and how much you need. A person at Geltides replies within two business days.

Apply for wholesaleOrder samples